StockStory highlights Boston Scientific as large-cap pick, flags Regeneron and Centene as sells

Industry
โดย StockStory·Read original
Summary · why it matters

StockStory identifies Boston Scientific as a large-cap stock with exciting potential, citing 15.7% average organic revenue growth over two years, 24.2% annual earnings per share growth over five years, and a 9.1 percentage point free cash flow margin expansion. The firm flags Regeneron and Centene as stocks to avoid, noting Regeneron’s 6.7% annual sales growth lagging peers and a 20.4 percentage point free cash flow margin decline, while Centene faces choppy customer growth and a 15.2% annual earnings per share drop despite revenue gains. Boston Scientific trades at 13.1 times forward earnings, Regeneron at 13.9 times, and Centene at 19.3 times.

Impact on stocks 3

Brain-Computer Interface▲ · 1 stocks
Boston Scientific Corp
BSX
▲ PositiveCapitalrelevance

StockStory highlights Boston Scientific as a large-cap pick with strong revenue and earnings growth, and expanding free cash flow margins.

Health Care▼ · 1 stocks
Centene Corp
CNC
▼ NegativeDemandrelevance

Centene faces choppy customer growth and a 15.2% annual earnings per share drop despite revenue gains, flagged as a stock to avoid.

Biotech & Genomic Medicine▼ · 1 stocks
Regeneron Pharmaceuticals Inc
REGN
▼ NegativeCapitalrelevance

Regeneron's 6.7% annual sales growth lags peers and free cash flow margin declined 20.4 percentage points, flagged as a stock to avoid.

© 2026 MarketDXNews